ダサチニブ医薬品の世界市場レポート 2025年

ダサチニブ医薬品市場規模は、今後数年で力強い成長が見込まれます。2029年にはCAGR6.6％で20億米ドルに成長します。予測期間の成長は、がん治療薬パイプラインへの投資の増加、薬剤耐性白血病の有病率の上昇、ジェネリックダサチニブ医薬品の利用可能性の増加、化学療法の副作用を最小限に抑えることへの注目の高まり、白血病に対する認識と早期診断の増加などに起因しています。予測期間における主な動向としては、個別化医療の導入、コンパニオン診断の導入、新しい製剤の開発、併用療法の進歩、バイオシミラーの開発などが挙げられます。

慢性骨髄性白血病（CML）の罹患率の上昇が、今後数年間におけるダサチニブ医薬品市場の成長を牽引すると予測されます。CMLは骨髄と血液に影響を及ぼすがんで、白血球の異常増殖を特徴とします。この有病率の増加は、生活習慣要因、食生活の乱れ、環境リスクの増大が大きく影響しています。ダサチニブは、制御不能な白血球の増殖をもたらすフィラデルフィア染色体変異に起因するチロシンキナーゼ蛋白質であるBCR-ABL遺伝子融合を阻害することにより、CMLの治療に有効です。例えば、2023年1月、米国がん学会は、米国におけるCML患者数が2022年の8,860人から8,930人に増加したと報告しました。このように、CMLの有病率の増加がダサチニブ医薬品市場を後押ししています。

ダサチニブ市場の主なプレーヤーは、市場でのプレゼンスを拡大し、手頃な価格の治療選択肢を提供し、患者へのアクセシビリティを高めるため、ジェネリック医薬品の開発に注力しています。ダサチニブのジェネリック医薬品は手ごろな価格で入手できるため、患者のアクセスが向上し、競争が促進されてヘルスケアコストの削減に貢献します。例えば、2024年9月、カナダの製薬会社Apotex Corp.は、成人および小児の特定のタイプの白血病の治療薬として、米国初のスプリセル（ダサチニブ）のジェネリック医薬品を発売しました。この開発により、ダサチニブ市場における価格競争が促進されると同時に、効果的な治療法へのアクセスが大幅に向上しました。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、新型コロナウイルス感染症、そして景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界ダサチニブ医薬品 PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のダサチニブ医薬品市場：成長率分析
• 世界のダサチニブ医薬品市場の実績：規模と成長, 2019-2024
• 世界のダサチニブ医薬品市場の予測：規模と成長, 2024-2029, 2034F
• 世界ダサチニブ医薬品総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のダサチニブ医薬品市場：製品タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• タブレット
• 経口懸濁液
• その他の製品
• 世界のダサチニブ医薬品市場：適応症別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 慢性骨髄性白血病
• 急性リンパ性白血病
• その他の適応症
• 世界のダサチニブ医薬品市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 専門クリニック
• 在宅ヘルスケア
• 世界のダサチニブ医薬品市場錠剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 20mg錠
• 50mg錠
• 70mg錠
• 80mg錠
• 世界のダサチニブ医薬品市場経口懸濁液のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 20 mgまたは5 mL経口懸濁液
• 40 mgまたは5 mL経口懸濁液
• 世界のダサチニブ医薬品市場、その他の製品のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 注射剤
• 併用療法
• ジェネリックダサチニブ製品

第7章 地域別・国別分析

• 世界のダサチニブ医薬品市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のダサチニブ医薬品市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• ダサチニブ医薬品市場：競合情勢
• ダサチニブ医薬品市場：企業プロファイル
  • Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • Gilead Sciences Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Teva Pharmaceutical Industries Ltd.
• Otsuka Pharmaceutical Co. Ltd.
• Sandoz Group AG
• Hetero Drugs Limited
• Sun Pharmaceutical Industries Limited
• MSN Laboratories Pvt. Ltd.
• Aurobindo Pharma Limited
• Dr. Reddy's Laboratories Limited
• Intas Pharmaceuticals Ltd.
• Cipla Limited
• Hikma Pharmaceuticals plc
• Lupin Limited
• Zhejiang Hisun Pharmaceutical Co. Ltd.
• Biocon Limited
• Alkem Laboratories Limited

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• ダサチニブ医薬品市場2029：新たな機会を提供する国
• ダサチニブ医薬品市場2029：新たな機会を提供するセグメント
• ダサチニブ医薬品市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Dasatinib medications are a form of targeted therapy classified as tyrosine kinase inhibitors, mainly utilized in the treatment of blood cancers such as chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). These drugs function by inhibiting proteins that promote cancer cell proliferation, which aids in slowing the progression of the disease. This results in enhanced survival rates and improved disease management.

The primary product types of dasatinib drugs include tablets, oral suspension, and other formulations. Dasatinib is predominantly available in tablet form, providing convenience for patients who need to take it orally. Its various applications encompass chronic myeloid leukemia, acute lymphoblastic leukemia, among others, with several end users such as hospitals, specialty clinics, and home healthcare providers.

The dasatinib drugs market research report is one of a series of new reports from The Business Research Company that provides dasatinib drugs market statistics, including dasatinib drugs industry global market size, regional shares, competitors with a dasatinib drugs market share, detailed dasatinib drugs market segments, market trends, and opportunities, and any further data you may need to thrive in the dasatinib drugs industry. This dasatinib drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The dasatinib drugs market size has grown strongly in recent years. It will grow from $1.45 billion in 2024 to $1.55 billion in 2025 at a compound annual growth rate (CAGR) of 6.9%. The growth in the historic period can be attributed to increase in prevalence of chronic myeloid leukemia (CML), growth in targeted cancer therapies, growth in research on tyrosine kinase inhibitors (TKIS), increase in investment in oncology research, and rise in number of clinical trials.

The dasatinib drugs market size is expected to see strong growth in the next few years. It will grow to $2 billion in 2029 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to increasing investment in oncology drug pipelines, rising prevalence of drug resistant leukemia cases, growing availability of generic dasatinib drugs, increasing focus on minimizing side effects of chemotherapy, and increasing awareness and early diagnosis of leukemia. Major trends in the forecast period include adoption of personalized medicine, implementation of companion diagnostics, development of new formulations, advancements in combination therapies, and development of biosimilars.

The rising incidence of chronic myeloid leukemia (CML) is projected to drive growth in the dasatinib drug market in the coming years. CML is a cancer that impacts the bone marrow and blood, characterized by the abnormal proliferation of white blood cells. This increase in prevalence is largely influenced by lifestyle factors, poor dietary habits, and growing environmental risks. Dasatinib is effective in treating CML by inhibiting the BCR-ABL gene fusion, a tyrosine kinase protein resulting from the Philadelphia chromosome mutation that leads to uncontrolled white blood cell growth. For example, in January 2023, the American Cancer Society reported that the number of CML cases in the United States rose to 8,930, up from 8,860 in 2022. Thus, the increasing prevalence of CML is fueling the dasatinib drug market.

Key players in the dasatinib market are concentrating on the development of generic drugs to expand their market presence, provide affordable treatment options, and enhance patient accessibility. Generic versions of dasatinib improve affordability, thus facilitating greater access for patients and fostering competition that can help lower healthcare costs. For instance, in September 2024, Apotex Corp., a Canadian pharmaceutical company, launched the first generic version of Sprycel (dasatinib) in the United States for treating specific types of leukemia in both adults and children. This development significantly enhances access to effective treatments while promoting price competition in the dasatinib market.

In August 2022, Bristol-Myers Squibb, a U.S.-based pharmaceutical company, acquired Turning Point Therapeutics Inc. for $4.1 billion. This acquisition bolsters BMS's cancer treatment portfolio by adding innovative therapies that target genetic mutations, thereby strengthening its position in the competitive lung cancer treatment arena. Turning Point Therapeutics Inc. specializes in developing next-generation tyrosine kinase inhibitors, including dasatinib, aimed at providing targeted therapies for cancer patients.

Major companies operating in the dasatinib drugs market are Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, Gilead Sciences Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Sandoz Group AG, Hetero Drugs Limited, Sun Pharmaceutical Industries Limited, MSN Laboratories Pvt. Ltd., Aurobindo Pharma Limited, Dr. Reddy's Laboratories Limited, Intas Pharmaceuticals Ltd., Cipla Limited, Hikma Pharmaceuticals plc, Lupin Limited, Zhejiang Hisun Pharmaceutical Co. Ltd., Biocon Limited, Alkem Laboratories Limited, Glenmark Pharmaceuticals Limited, Torrent Pharmaceuticals Limited, Alembic Pharmaceuticals Limited, Mylan N.V., Manus Aktteva Biopharma LLP

North America was the largest region in the dasatinib drugs market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the dasatinib drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the dasatinib drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The dasatinib drugs market consists of sales of sprycel and generic dasatinib. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Dasatinib Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on dasatinib drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for dasatinib drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The dasatinib drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product Type: Tablets; Oral Suspension; Other Products
• 2) By Indication: Chronic Myeloid Leukemia; Acute Lymphoblastic Leukemia; Other Indications
• 3) By End User: Hospitals; Specialty Clinics; Home Healthcare
• Subsegments:
• 1) By Tablets: 20 mg Tablets; 50 mg Tablets; 70 mg Tablets; 80 mg Tablets
• 2) By Oral Suspension: 20 mg Or 5 mL Oral Suspension; 40 mg Or 5 mL Oral Suspension
• 3) By Other Products: Injectable Formulations; Combination Therapies; Generic Dasatinib Products
• Companies Mentioned: Bristol-Myers Squibb Company; AstraZeneca plc; Novartis AG; Gilead Sciences Inc.; Amgen Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Dasatinib Drugs Market Characteristics

3. Dasatinib Drugs Market Trends And Strategies

4. Dasatinib Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Dasatinib Drugs Growth Analysis And Strategic Analysis Framework

• 5.1. Global Dasatinib Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Dasatinib Drugs Market Growth Rate Analysis
• 5.4. Global Dasatinib Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Dasatinib Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Dasatinib Drugs Total Addressable Market (TAM)

6. Dasatinib Drugs Market Segmentation

• 6.1. Global Dasatinib Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tablets
• Oral Suspension
• Other Products
• 6.2. Global Dasatinib Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chronic Myeloid Leukemia
• Acute Lymphoblastic Leukemia
• Other Indications
• 6.3. Global Dasatinib Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Home Healthcare
• 6.4. Global Dasatinib Drugs Market, Sub-Segmentation Of Tablets, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20 mg Tablets
• 50 mg Tablets
• 70 mg Tablets
• 80 mg Tablets
• 6.5. Global Dasatinib Drugs Market, Sub-Segmentation Of Oral Suspension, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20 mg Or 5 mL Oral Suspension
• 40 mg Or 5 mL Oral Suspension
• 6.6. Global Dasatinib Drugs Market, Sub-Segmentation Of Other Products, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Injectable Formulations
• Combination Therapies
• Generic Dasatinib Products

7. Dasatinib Drugs Market Regional And Country Analysis

• 7.1. Global Dasatinib Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Dasatinib Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Dasatinib Drugs Market

• 8.1. Asia-Pacific Dasatinib Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Dasatinib Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Dasatinib Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Dasatinib Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Dasatinib Drugs Market

• 9.1. China Dasatinib Drugs Market Overview
• 9.2. China Dasatinib Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Dasatinib Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Dasatinib Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Dasatinib Drugs Market

• 10.1. India Dasatinib Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Dasatinib Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Dasatinib Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Dasatinib Drugs Market

• 11.1. Japan Dasatinib Drugs Market Overview
• 11.2. Japan Dasatinib Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Dasatinib Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Dasatinib Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Dasatinib Drugs Market

• 12.1. Australia Dasatinib Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Dasatinib Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Dasatinib Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Dasatinib Drugs Market

• 13.1. Indonesia Dasatinib Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Dasatinib Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Dasatinib Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Dasatinib Drugs Market

• 14.1. South Korea Dasatinib Drugs Market Overview
• 14.2. South Korea Dasatinib Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Dasatinib Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Dasatinib Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Dasatinib Drugs Market

• 15.1. Western Europe Dasatinib Drugs Market Overview
• 15.2. Western Europe Dasatinib Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Dasatinib Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Dasatinib Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Dasatinib Drugs Market

• 16.1. UK Dasatinib Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Dasatinib Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Dasatinib Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Dasatinib Drugs Market

• 17.1. Germany Dasatinib Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Dasatinib Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Dasatinib Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Dasatinib Drugs Market

• 18.1. France Dasatinib Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Dasatinib Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Dasatinib Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Dasatinib Drugs Market

• 19.1. Italy Dasatinib Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Dasatinib Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Dasatinib Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Dasatinib Drugs Market

• 20.1. Spain Dasatinib Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Dasatinib Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Dasatinib Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Dasatinib Drugs Market

• 21.1. Eastern Europe Dasatinib Drugs Market Overview
• 21.2. Eastern Europe Dasatinib Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Dasatinib Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Dasatinib Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Dasatinib Drugs Market

• 22.1. Russia Dasatinib Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Dasatinib Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Dasatinib Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Dasatinib Drugs Market

• 23.1. North America Dasatinib Drugs Market Overview
• 23.2. North America Dasatinib Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Dasatinib Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Dasatinib Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Dasatinib Drugs Market

• 24.1. USA Dasatinib Drugs Market Overview
• 24.2. USA Dasatinib Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Dasatinib Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Dasatinib Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Dasatinib Drugs Market

• 25.1. Canada Dasatinib Drugs Market Overview
• 25.2. Canada Dasatinib Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Dasatinib Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Dasatinib Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Dasatinib Drugs Market

• 26.1. South America Dasatinib Drugs Market Overview
• 26.2. South America Dasatinib Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Dasatinib Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Dasatinib Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Dasatinib Drugs Market

• 27.1. Brazil Dasatinib Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Dasatinib Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Dasatinib Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Dasatinib Drugs Market

• 28.1. Middle East Dasatinib Drugs Market Overview
• 28.2. Middle East Dasatinib Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Dasatinib Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Dasatinib Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Dasatinib Drugs Market

• 29.1. Africa Dasatinib Drugs Market Overview
• 29.2. Africa Dasatinib Drugs Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Dasatinib Drugs Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Dasatinib Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Dasatinib Drugs Market Competitive Landscape And Company Profiles

• 30.1. Dasatinib Drugs Market Competitive Landscape
• 30.2. Dasatinib Drugs Market Company Profiles
  • 30.2.1. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Gilead Sciences Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Dasatinib Drugs Market Other Major And Innovative Companies

• 31.1. Teva Pharmaceutical Industries Ltd.
• 31.2. Otsuka Pharmaceutical Co. Ltd.
• 31.3. Sandoz Group AG
• 31.4. Hetero Drugs Limited
• 31.5. Sun Pharmaceutical Industries Limited
• 31.6. MSN Laboratories Pvt. Ltd.
• 31.7. Aurobindo Pharma Limited
• 31.8. Dr. Reddy's Laboratories Limited
• 31.9. Intas Pharmaceuticals Ltd.
• 31.10. Cipla Limited
• 31.11. Hikma Pharmaceuticals plc
• 31.12. Lupin Limited
• 31.13. Zhejiang Hisun Pharmaceutical Co. Ltd.
• 31.14. Biocon Limited
• 31.15. Alkem Laboratories Limited

32. Global Dasatinib Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Dasatinib Drugs Market

34. Recent Developments In The Dasatinib Drugs Market

35. Dasatinib Drugs Market High Potential Countries, Segments and Strategies

• 35.1 Dasatinib Drugs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Dasatinib Drugs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Dasatinib Drugs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer